AJITO Keiichi
No ORCID on file
· 16 papers in corpus
· active 1997-1998
Frequent coauthors
- KURIHARA Kenichi 16
- MIYAJIMA KAORI 16
- OKONOGI TSUNEO 16
- SHINEI RIE 16
- TANABE Kiyoshi 16
- TATSUTA Kuniaki 16
- TABATA Yuji 16
- YASUDA SHOHEI 16
- YAMAMOTO Yasuo 16
1998
Compounds represented by the following formula (I) and pharmaceutically acceptable salts thereof are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used as therapeutic and prophylactic age…
1998
Compounds represented by the following formula (I) and pharmaceutically acceptable salts thereof are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used as therapeutic and prophylactic age…
1998
Compounds represented by the following formula (I) and pharmaceutically acceptable salts thereof are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used as therapeutic and prophylactic age…
1998
Compounds represented by the following formula (I) and pharmaceutically acceptable salts thereof are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used as therapeutic and prophylactic age…
1998
Compounds represented by the following formula (I) and pharmaceutically acceptable salts thereof are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used as therapeutic and prophylactic age…
1998
Compounds represented by the following formula (I) and pharmaceutically acceptable salts thereof are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used as therapeutic and prophylactic age…
1998
Compounds represented by the following formula (I) and pharmaceutically acceptable salts thereof are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used as therapeutic and prophylactic age…
1998
Compounds represented by the following formula (I) and pharmaceutically acceptable salts thereof are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used as therapeutic and prophylactic age…
1997
Compounds represented by general formula (I) and pharmaceutically acceptable salts thereof, which have progesterone receptor binding inhibitory activities and so are used as remedies and preventives for diseases in which progesterone partic…
1997
Compounds represented by general formula (I) and pharmaceutically acceptable salts thereof, which have progesterone receptor binding inhibitory activities and so are used as remedies and preventives for diseases in which progesterone partic…
1997
Compounds represented by general formula (I) and pharmaceutically acceptable salts thereof, which have progesterone receptor binding inhibitory activities and so are used as remedies and preventives for diseases in which progesterone partic…
1997
Compounds represented by general formula (I) and pharmaceutically acceptable salts thereof, which have progesterone receptor binding inhibitory activities and so are used as remedies and preventives for diseases in which progesterone partic…
1997
Compounds represented by general formula (I) and pharmaceutically acceptable salts thereof, which have progesterone receptor binding inhibitory activities and so are used as remedies and preventives for diseases in which progesterone partic…
1997
Compounds represented by general formula (I) and pharmaceutically acceptable salts thereof, which have progesterone receptor binding inhibitory activities and so are used as remedies and preventives for diseases in which progesterone partic…
1997
Compounds represented by general formula (I) and pharmaceutically acceptable salts thereof, which have progesterone receptor binding inhibitory activities and so are used as remedies and preventives for diseases in which progesterone partic…
1997
Compounds represented by general formula (I) and pharmaceutically acceptable salts thereof, which have progesterone receptor binding inhibitory activities and so are used as remedies and preventives for diseases in which progesterone partic…